BIOMARKERS FOR OSTEOARTHRITIS

骨关节炎的生物标志物

• 批准号: 7675027
• 负责人: LINDA J SANDELL
• 金额: $ 5万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7675027
• 关键词: Age; American; Analgesics; Biochemical; Biological Assay; Biological Markers; Blood Circulation; Clinical Research; Clinical Trials; Data; Databases; Degenerative polyarthritis; Development; Diagnosis; Disease; Disease Marker; Disease Progression; Educational workshop; Enrollment; Genetic; Gold; Health; Imaging Techniques; Joints; Knee; Laboratories; Magnetic Resonance Imaging; Malignant Neoplasms; Medicine; Metabolism; Natural History; Pain; Pharmaceutical Preparations; Population Study; Replacement Arthroplasty; Reporting; Research; Roentgen Rays; Societies; Staging; Surface; Symptoms; Testing; Therapeutic; Urine; Validation; Woman; arthropathies; articular cartilage; disability; disease diagnosis; disorder risk; follow-up; genome wide association study; imaging modality; interest; meetings; men; novel; repository; research clinical testing; standardize measure; treatment planning; web site

DESCRIPTION (provided by applicant): Osteoarthritis is the most common disorder of the synovial joint, causing pain and disability in an estimated 12 percent of Americans age 25 and older and 30% of those over 60. The most widely used treatments are analgesic medications to relieve pain symptoms and ultimately, joint replacement. The OsteoArthritis Initiative (OAI) was established in 2000 as a knee health study to establish and maintain a natural history database for osteoarthritis that includes clinical evaluation data, radiological (x-ray and magnetic resonance) images, and a biospecimen repository from 4796 men and women ages 45-79 enrolled between February 2004 and May 2006. At present there are no laboratory tests to help make or confirm an OA diagnosis, predict the progression of OA or determine whether therapies may be altering the course of the disease. The field of biomarkers for OA is relatively new, and recently developed markers for OA diagnosis and progression are currently being tested. At this point, exciting new results are available on study populations and novel biomarkers have been discovered. Following up on the successful NIAMS/NIA sponsored Biomarkers Network Workshops in 2004, 2005 and 2006, three additional OA Biomarker Workshops are planned over the next four years. They will occur approximately every 18 months and cover the range of current interests in the biomarkers field. "The initial meeting will be a direct continuation of the previous meetings wherein current research on biochemical biomarkers and results of clinical studies using the biomarkers will be reported as well as new validation criteria. " The second OA Biomarker Workshop will highlight the recent exciting advances in the genetics of OA and the use of genome wide screening to identify new targets for biomarkers of disease, risk of disease, and therapeutics. "The third OA Biomarker Workshop will highlight the use of imaging modalities such as X-rays, MRI and other imaging techniques as biomarkers for OA. A Website will be established that highlights information related to biomarkers. In many other fields of medicine, in particular cancer, biomarkers have become the gold standard in the diagnosis and analysis of progression of disease. With OA having such a high impact on our society, it is critical that valid biomarkers be developed that will allow proper planning of treatment of the disease and encourage the development of disease-modifying drugs.

描述（由申请人提供）：骨关节炎是滑膜关节最常见的疾病，估计在25岁及60岁以上的美国人中，估计有12％的美国人在60岁以上的美国人中引起疼痛和残疾。使用最广泛的治疗方法是止痛药，可缓解疼痛症状并最终替代。骨关节炎倡议（OAI）是在2000年建立的，是一项膝盖健康研究，旨在建立和维护骨关节炎的自然历史数据库，其中包括临床评估数据，放射学数据（X射线和磁共振）图像，以及4796年4796年2月2日在4796年的男性妇女的生物兴趣库，并在其45-79年2月在2004年2月2004年之间进行了2004年2月2004年的测试。进行或确认OA诊断，预测OA的进展或确定疗法是否可能正在改变疾病的进展。 OA的生物标志物领域是相对较新的，目前正在测试OA诊断和进展的最近开发的标记。在这一点上，研究人群可获得令人兴奋的新结果，并发现了新的生物标志物。跟进2004年，2005年和2006年成功的NIAMS/NIA赞助生物标志物网络研讨会，计划在未来四年内额外举办三个OA生物标志物研讨会。它们将每18个月大约发生一次，并涵盖生物标志物领域的当前利益范围。 “初次会议将是先前的会议的直接延续，在该会议上，将报道对使用生物标志物的生物化学生物标志物以及临床研究的结果以及新的验证标准。”第二个OA生物标志物研讨会将突出鉴定新宗教疾病的遗传和疾病的遗传疾病和疾病的使用，这将强调最近在Genome Genotics的遗传学方面的令人兴奋的进步，并鉴定出了新的疾病。 “第三个OA生物标志物研讨会将强调使用成像模式，例如X射线，MRI和其他成像技术作为OA的生物标志物。将建立一个网站，突出一个与生物标志物有关的信息。在许多其他医学领域，在许多其他领域，尤其是癌症，生物标志物在癌症中的诊断和疾病的影响很高，这是OA的重要性，它具有oa的影响。开发生物标志物，将允许对疾病的治疗进行适当的计划，并鼓励开发疾病改良药物。